The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK

Tags

AbbVie Employees Donate more than 26,000 Hours in One Week to Communities Around the World

Press releases   •   Jun 26, 2017 00:01 BST

AbbVie UK joins colleagues around the world to make a difference in the lives of the underserved. More than 6,000 AbbVie employees in more than 50 countries will volunteer more than 26,000 service hours to make a difference in local communities during AbbVie’s Week of Possibilities.

AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jun 23, 2017 00:01 BST

If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)

AbbVie Appoints New General Manager in U.K.

AbbVie Appoints New General Manager in U.K.

Press releases   •   Jun 19, 2017 00:01 BST

Jérôme Bouyer has been appointed General Manager, AbbVie U.K.

Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan- genotypic Regimen for Chronic Hepatitis C – the First EAMS in HCV

Press releases   •   May 10, 2017 00:01 BST

AbbVie’s glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic, ribavirin-free regimen being evaluated by the European Medicine’s Agency as a cure for hepatitis C virus (HCV) infection in patients across all genotypes (GT)

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

Press releases   •   May 04, 2017 00:01 BST

AbbVie’s new Live:Lab programme launches today and aims to improve the nation’s health through addressing the ‘Fear of Finding Out’ - focusing on prevention

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR12 Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C

Press releases   •   Apr 21, 2017 00:01 BST

95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR12 with 8 weeks of treatment

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR12 Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

Press releases   •   Apr 20, 2017 00:01 BST

New data demonstrated high SVR12 rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment

NHS England to routinely commission AbbVie’s HUMIRA® (adalimumab) for adults with severe refractory uveitis

Press releases   •   Mar 13, 2017 00:01 GMT

NHS England publishes Interim Clinical Commissioning Policy recommending AbbVie’s HUMIRA® (adalimumab) for adults with severe refractory uveitis

AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C

Press releases   •   Feb 27, 2017 00:01 GMT

CHMP opinion grants AbbVie approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis

‘Fear of Finding Out’ Makes up a Third of Conscious Reasons Why We Don’t Visit The Doctor

‘Fear of Finding Out’ Makes up a Third of Conscious Reasons Why We Don’t Visit The Doctor

Press releases   •   Jan 30, 2017 16:00 GMT

Unhealthy people are less likely to visit the GP due to the ‘Fear of Finding Out'

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorisation Application for AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jan 24, 2017 00:01 GMT

If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis